PMID- 28382143
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240325
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 8
IP  - 5
DP  - 2017
TI  - Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index of Overall 
      Survival in Cisplatin-based Chemotherapy-treated Patients with Metastatic 
      Nasopharyngeal Carcinoma.
PG  - 809-815
LID - 10.7150/jca.17536 [doi]
AB  - The Albumin-to-Alkaline Phosphatase Ratio (AAPR) has been recently revealed as a 
      prognostic index for hepatocellular carcinoma, whereas its role in metastatic 
      nasopharyngeal cancer (NPC) remains unclear. The aim of this study was to 
      evaluate the clinical value of AAPR in patients with metastatic NPC. We 
      retrospectively reviewed 209 metastatic NPC patients treated with cisplatin-based 
      regimens. Survival data were calculated using the Kaplan-Meier method and were 
      compared using the log-rank test. Univariate and multivariate survival analyses 
      were conducted using the Cox proportional hazards regression methodology. The 
      optimal cutoff level of AAPR for assessing overall survival (OS) was 0.447, which 
      was determined by R software. An AAPR less than 0.447 was significantly 
      associated with a higher lactate dehydrogenase (LDH) level (273 vs. 185 U/L, P = 
      0.004), a higher EBV DNA viral load (5.59x10(5) vs. 3.49x10(4) copies/ml, P = 
      0.001), and more liver and bone metastases (P = 0.005 and P = 0.001, 
      respectively). Additionally, patients with an AAPR < 0.447 had a shorter overall 
      survival and progression-free survival (hazard ratio: 3.269, 95% confidence 
      interval: 1.710-6.248; HR: 2.295, 95% confidence interval: 1.217-4.331, 
      respectively) than those with an AAPR >/= 0.447. Our study suggested that the AAPR 
      might be a novel prognostic factor in metastatic NPC patients treated with 
      cisplatin-based regimens. However, a prospective study to validate its prognostic 
      value is needed, and the mechanisms underlying the low AAPR and poor survival in 
      metastatic NPC need to be further investigated.
FAU - Nie, Man
AU  - Nie M
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Sun, Peng
AU  - Sun P
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Chen, Cui
AU  - Chen C
AD  - Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, 
      Guangzhou 510060, Guangdong, People's Republic of China.
FAU - Bi, Xiwen
AU  - Bi X
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Yang, Hang
AU  - Yang H
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Liu, Panpan
AU  - Liu P
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Li, Zhiming
AU  - Li Z
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Xia, Yi
AU  - Xia Y
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
FAU - Jiang, Wenqi
AU  - Jiang W
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 
      510060, Guangdong, People's Republic of China;; State Key Laboratory of Oncology 
      in South China, Guangzhou 510060, Guangdong, People's Republic of China;; 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170225
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC5381169
OTO - NOTNLM
OT  - Albumin-to-alkaline phosphatase ratio
OT  - cisplatin-based regimens
OT  - metastatic nasopharyngeal carcinoma.
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2017/04/07 06:00
MHDA- 2017/04/07 06:01
PMCR- 2017/01/01
CRDT- 2017/04/07 06:00
PHST- 2016/09/11 00:00 [received]
PHST- 2016/10/29 00:00 [accepted]
PHST- 2017/04/07 06:00 [entrez]
PHST- 2017/04/07 06:00 [pubmed]
PHST- 2017/04/07 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - jcav08p0809 [pii]
AID - 10.7150/jca.17536 [doi]
PST - epublish
SO  - J Cancer. 2017 Feb 25;8(5):809-815. doi: 10.7150/jca.17536. eCollection 2017.